e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Antimicrobial treatment and resistance in lower respiratory tract infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial
D. Snijders, C. de Graaff, T. van der Werf, W. Boersma (Alkmaar, Groningen, Netherlands)
Source:
Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Session:
Antimicrobial treatment and resistance in lower respiratory tract infections
Session type:
Thematic Poster Session
Number:
2567
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Snijders, C. de Graaff, T. van der Werf, W. Boersma (Alkmaar, Groningen, Netherlands). Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial. Eur Respir J 2011; 38: Suppl. 55, 2567
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice.
Source: International Congress 2017 – COPD management
Year: 2017
The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia
Year: 2007
A worldwide perspective of the level of compliance with guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO cohort international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome
Source: Eur Respir J 2008; 32: 892-901
Year: 2008
Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease
Source: International Congress 2019 – M-health/e-health I
Year: 2019
Is severity index enough to assess hospital admission of community-acquired pneumonia (CAP) patients?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis
Source: Eur Respir J 2011; 37: 858-864
Year: 2011
Can CAP guideline adherence improve patient outcome in internal medicine departments?
Source: Eur Respir J 2008; 32: 902-910
Year: 2008
Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
Adherence to guidelines and clinical stability in community-acquired pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 41s
Year: 2007
Validation of treatment adequacy of current guidelines for hospital-acquired pneumonia
Source: Annual Congress 2003 - Epidemiology, therapy and outcome of infections in the ICU
Year: 2003
Severe community-acquired pneumonia (CAP): validation of the IDSA/ATS guidelines to predict admission to the ICU
Source: Annual Congress 2008 - Diagnosis and outcome in critically ill patients
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept